Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

Abstract Introduction The International Psoriasis Council (IPC) reclassified patients eligible for systemic therapy to include those with body surface area (BSA) > 10%, psoriasis lesions in high-impact areas, or failure of topical therapy. Risankizumab is an interleukin-23 inhibitor approved for the...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Bruce Strober, Manish Patel, Mark I. Kaldas, Greg St. John, Huzefa Photowala, Adam P. Sima, Thomas Eckmann, Alicia Beeghly, April Armstrong
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Adis, Springer Healthcare 2025-07-01
סדרה:	Dermatology and Therapy
נושאים:	CorEvitas Psoriasis Registry International Psoriasis Council disease reclassification National Psoriasis Foundation treat-to-target goals Patient-reported outcomes Psoriasis Real-world
גישה מקוונת:	https://doi.org/10.1007/s13555-025-01474-3
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!